Intratumoral Injection of SD-101, an Immunostimulatory CpG, in Combination With BMS-986178 and Local Radiation in Low-Grade B-Cell Lymphomas

Trial Profile

Intratumoral Injection of SD-101, an Immunostimulatory CpG, in Combination With BMS-986178 and Local Radiation in Low-Grade B-Cell Lymphomas

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Mar 2018

At a glance

  • Drugs BMS 986178 (Primary) ; SD 101 Dynavax (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Feb 2018 Planned End Date changed from 1 Aug 2020 to 1 Sep 2020.
    • 23 Feb 2018 Planned primary completion date changed from 1 Aug 2020 to 1 Sep 2020.
    • 23 Feb 2018 Planned initiation date changed from 1 Feb 2018 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top